Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

Radiotherapy and Oncology ◽

10.1016/j.radonc.2011.05.013 ◽

2011 ◽

Vol 100 (1) ◽

pp. 86-92 ◽

Author(s):

Lisa Lowry ◽

Paul Smith ◽

Wendi Qian ◽

Stephen Falk ◽

Kim Benstead ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Local Control ◽

Phase Iii ◽

Phase Iii Trial ◽

Reduced Dose ◽

Non Hodgkin Lymphoma

Download Full-text

O07 Dexamethasone versus methyl-prednisolone for adult acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL) in patients ≤60 yrs old: final results of the EORTC ALL-4 Phase III Trial

Blood Reviews ◽

10.1016/s0268-960x(07)70025-5 ◽

2007 ◽

Vol 21 ◽

pp. S69

Author(s):

B. Labar ◽

S. Suciu ◽

P. Muus ◽

R. Willemze ◽

J.-P. Marie ◽

...

Keyword(s):

Acute Lymphoblastic Leukaemia ◽

Hodgkin Lymphoma ◽

Lymphoblastic Leukaemia ◽

Phase Iii ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma ◽

Methyl Prednisolone

Download Full-text

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

10.1186/1471-2407-9-153 ◽

2009 ◽

Vol 9 (1) ◽

Author(s):

Rohini Sharma ◽

David Cunningham ◽

Paul Smith ◽

Graham Robertson ◽

Owen Dent ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Iii ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma

Download Full-text

R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.8000 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 8000-8000 ◽

Author(s):

D. Cunningham ◽

P. Smith ◽

P. Mouncey ◽

W. Qian ◽

A. S. Jack ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Phase Iii ◽

Newly Diagnosed ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma ◽

Download Full-text

Faculty Opinions recommendation of Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1047408.497353 ◽

2006 ◽

Author(s):

John Sweetenham

Keyword(s):

Hodgkin Lymphoma ◽

Initial Treatment ◽

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma

Download Full-text

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)

Annals of Oncology ◽

10.1093/annonc/mdl153 ◽

2006 ◽

Vol 17 (10) ◽

pp. 1546-1552 ◽

Author(s):

D.C. Betticher ◽

G. Martinelli ◽

J.A. Radford ◽

M. Kaufmann ◽

M.J.S. Dyer ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Initial Treatment ◽

High Dose Chemotherapy ◽

Phase Iii ◽

High Dose ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma

Download Full-text

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

British Journal of Haematology ◽

10.1111/bjh.14101 ◽

2016 ◽

Vol 174 (5) ◽

pp. 692-699 ◽

Author(s):

Ruth Pettengell ◽

Catherine Sebban ◽

Pier Luigi Zinzani ◽

Hans Gunter Derigs ◽

Sergey Kravchenko ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Phase Iii ◽

Phase Iii Trial ◽

Non Hodgkin Lymphoma ◽

Download Full-text

Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951

Haematologica ◽

10.3324/haematol.2017.165845 ◽

2017 ◽

Vol 102 (10) ◽

pp. 1727-1738 ◽

Author(s):

Veerle Mondelaers ◽

Stefan Suciu ◽

Barbara De Moerloose ◽

Alina Ferster ◽

Françoise Mazingue ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Hodgkin Lymphoma ◽

Lymphoblastic Leukemia ◽

Childhood Acute Lymphoblastic Leukemia ◽

Phase Iii ◽

Phase Iii Trial ◽

E Coli ◽

Non Hodgkin Lymphoma

Download Full-text

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

International Journal of Hematology ◽

10.1007/s12185-019-02802-y ◽

2019 ◽

Vol 111 (3) ◽

pp. 409-416 ◽

Author(s):

Koji Izutsu ◽

Yosuke Minami ◽

Noriko Fukuhara ◽

Yasuhito Terui ◽

Tatsuro Jo ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Japanese Patients ◽

Phase Iii ◽

Non Hodgkin Lymphoma ◽

Phase Iii Study

Download Full-text

Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.8001 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 8001-8001 ◽

Author(s):

P. J. Stiff ◽

J. M. Unger ◽

J. Cook ◽

L. S. Constine ◽

S. Couban ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Iii ◽

Non Hodgkin Lymphoma ◽

Intergroup Trial

Download Full-text

ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps7587 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS7587-TPS7587

Author(s):

Michael Brady ◽

Myla S. Strawderman ◽

Christopher Flowers ◽

Brad S. Kahl ◽

John Paul Leonard ◽

...

Keyword(s):

Vitamin D ◽

Randomized Trial ◽

Hodgkin Lymphoma ◽

Progression Free Survival ◽

Tumor Burden ◽

Phase Iii ◽

Indolent Lymphoma ◽

Double Blind ◽

Free Survival ◽

Non Hodgkin Lymphoma

Download Full-text